GW Henssler & Associates Ltd. Raises Position in Sanofi (NASDAQ:SNY)

GW Henssler & Associates Ltd. grew its position in Sanofi (NASDAQ:SNY) by 2.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 151,805 shares of the company’s stock after acquiring an additional 4,305 shares during the period. GW Henssler & Associates Ltd.’s holdings in Sanofi were worth $7,508,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Cardinal Capital Management Inc. purchased a new stake in Sanofi during the first quarter worth about $25,000. Reby Advisors LLC purchased a new stake in Sanofi during the fourth quarter worth about $35,000. Arkadios Wealth Advisors purchased a new stake in Sanofi during the fourth quarter worth about $36,000. Charter Oak Capital Management LLC purchased a new stake in Sanofi during the fourth quarter worth about $40,000. Finally, JJJ Advisors Inc. raised its position in Sanofi by 193.8% during the fourth quarter. JJJ Advisors Inc. now owns 852 shares of the company’s stock worth $41,000 after acquiring an additional 562 shares during the last quarter. 6.93% of the stock is currently owned by institutional investors and hedge funds.

SNY stock traded down $0.32 on Tuesday, hitting $50.57. 9,863 shares of the company were exchanged, compared to its average volume of 2,294,616. Sanofi has a twelve month low of $44.76 and a twelve month high of $55.00. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.85 and a quick ratio of 1.38. The business’s fifty day moving average is $50.43 and its two-hundred day moving average is $48.86. The stock has a market capitalization of $127.33 billion, a price-to-earnings ratio of 21.74, a price-to-earnings-growth ratio of 1.90 and a beta of 0.55.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Wednesday, April 28th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.83 by $0.14. Sanofi had a net margin of 14.49% and a return on equity of 24.77%. The firm had revenue of $8.59 billion during the quarter, compared to analyst estimates of $8.48 billion. During the same quarter in the prior year, the business posted $1.63 earnings per share. Sanofi’s revenue for the quarter was down 4.3% compared to the same quarter last year. Equities research analysts expect that Sanofi will post 3.49 earnings per share for the current year.

The business also recently declared an annual dividend, which will be paid on Wednesday, May 26th. Investors of record on Tuesday, May 4th will be given a dividend of $1.9061 per share. This is a positive change from Sanofi’s previous annual dividend of $1.21. The ex-dividend date is Monday, May 3rd. This represents a yield of 3.2%. Sanofi’s dividend payout ratio is 35.24%.

SNY has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Sanofi in a research report on Friday. UBS Group restated a “buy” rating on shares of Sanofi in a research report on Tuesday, January 19th. Barclays restated an “equal weight” rating on shares of Sanofi in a research report on Thursday, April 29th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Sanofi in a research report on Wednesday, February 10th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $53.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.

Read More: What is the CBOE Russell 2000® Volatility Index?

Want to see what other hedge funds are holding SNY? Visit to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with's FREE daily email newsletter.